BCL2A1 and diffuse large B-cell lymphoma: However, it might be an attractive target in some types of blood cancer, such as diffuse large B‐cell lymphoma (DLBCL) or myeloid malignancies as well as melanoma skin cancer, as these tumors appear to frequently use aberrant expression of BFL1 to secure survival 131.